906366-79-8 Usage
Description
Inotilone is a potent COX-2 inhibitor, which is a type of enzyme involved in the production of prostaglandins, hormone-like substances that play a role in inflammation and pain. It is used for treating degenerative conditions resulting from the overexpression of iNOS, an enzyme that produces nitric oxide and is associated with inflammation and tissue damage.
Uses
Used in Pharmaceutical Industry:
Inotilone is used as an anti-inflammatory agent for treating degenerative conditions caused by overexpression of iNOS. Its COX-2 inhibitory properties help in reducing inflammation and pain associated with these conditions.
Used in Pain Management:
Inotilone is used as a pain reliever for managing chronic pain and inflammation resulting from various conditions, such as arthritis, muscle pain, and other inflammatory disorders.
Used in Neuroprotection:
Inotilone is used as a neuroprotective agent for preventing neuronal damage and degeneration caused by excessive nitric oxide production due to iNOS overexpression. This makes it a potential candidate for treating neurodegenerative diseases, such as Alzheimer's and Parkinson's.
Used in Cancer Therapy:
Inotilone is used as an adjunct therapy in cancer treatment to reduce inflammation and pain associated with cancer and its treatment. Its COX-2 inhibitory properties can also help in reducing the side effects of chemotherapy and radiation therapy.
Used in Cardiovascular Disease Management:
Inotilone is used as a cardioprotective agent for managing inflammation and oxidative stress associated with cardiovascular diseases, such as atherosclerosis, hypertension, and heart failure. Its anti-inflammatory properties can help in reducing the risk of cardiovascular events and improving overall heart health.
Biological Activity
inotilone is a cyclooxygenase (cox) inhibitor.many of nonsteroidal anti-inflammatory drugs (nsaids) target cyclooxygenases (cox), which catalyze the first two steps in the biosynthesis of the prostaglandins from the substrate arachidonic acid.
in vitro
inotilone was tested as the inhibitor of mitogen-activated protein kinase, nuclear factor-κb (nf-κb), and matrix-metalloproteinase (mmp)-9 protein expressions in lps-stimulated raw264.7 cells. when raw264.7 macrophages were treated with inotilone with lps, a significant concentration-dependent inhibition of no production was detected. it was also found that inotilone could block the protein expression of inos, nf-κb, and mmp-9 in lps-stimulated raw264.7 macrophages [1].
in vivo
in in vivo tests, inotilone decreased the paw edema after carr administration, and it increased the activities of catalase (cat), superoxide dismutase (sod), and glutathione peroxidase (gpx). inotilone also significantly attenuated the malondialdehyde (mda) level in the edema paw. inotilone decreased the no and tumor necrosis factor (tnf-α) levels on serum after carr injection. in addition, an intraperitoneal injection treatment with inotilone could diminish neutrophil infiltration into sites of inflammation, as did indomethacin [1].
IC 50
0.03 and 0.36 μm for cox-2 and cox-1, respectively
references
[1] huang gj, huang ss, deng js. anti-inflammatory activities of inotilone from phellinus linteus through the inhibition of mmp-9, nf-κb, and mapk activation in vitro and in vivo. plos one. 2012;7(5):e35922.
Check Digit Verification of cas no
The CAS Registry Mumber 906366-79-8 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,0,6,3,6 and 6 respectively; the second part has 2 digits, 7 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 906366-79:
(8*9)+(7*0)+(6*6)+(5*3)+(4*6)+(3*6)+(2*7)+(1*9)=188
188 % 10 = 8
So 906366-79-8 is a valid CAS Registry Number.
906366-79-8Relevant articles and documents
Inotilone derivatives as coherent biological response modifier (cBMR)
-
, (2011/04/14)
Optimal compositions of derivatives of 5-methyl-3(2H)-furanone compounds and phenylpropanoid polyketides related to inotilone, that exert biological response modification in health and disease, and their method of preparation, are disclosed. Methods of tr
Convergent synthesis of potent COX-2 inhibitor inotilone
Shamshina, Julia L.,Snowden, Timothy S.
, p. 3767 - 3769 (2008/02/06)
The first synthesis of potent COX-2 inhibitor inotilone is reported. The convergent route features a Mukaiyama aldol condensation that generates the target without the use of protecting groups or a separate dehydration step. The approach also highlights a
